Status:
TERMINATED
A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography
Lead Sponsor:
Forest Laboratories
Conditions:
Heart Disease
Ischemic Heart Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to determine whether BMS068645 is as effective as Adenosine SPECT at detecting blockages in heart arteries, and to determine if it will have fewer side effects
Eligibility Criteria
Inclusion
- Referral for pharmacologic stress SPECT MPI
- Have suspected Ischemic heart disease
Exclusion
- Acute myocardial Infarction, Coronary artery bypass graft, percutaneous coronary intervention within 30 days of enrollment
- Severe asthma or COPD
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT00162084
Start Date
April 1 2005
Last Update
February 1 2017
Active Locations (77)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Birmingham, Alabama, United States, 35213
2
Local Institution
Huntsville, Alabama, United States, 35801
3
Local Institution
North Little Rock, Arkansas, United States, 72117
4
Local Institution
Northridge, California, United States, 91325